Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs.

@article{Edwards2008UpdatedRF,
  title={Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs.},
  author={Beatrice Edwards and John W. Hellstein and Peter L. Jacobsen and Steven Kaltman and Angelo J. Mariotti and C{\'e}sar Augusto Migliorati},
  journal={Journal of the American Dental Association},
  year={2008},
  volume={139 12},
  pages={
          1674-7
        }
}
BACKGROUND and Overview. In 2005, the American Dental Association (ADA) Council on Scientific Affairs convened an expert panel to develop clinical recommendations for dentists treating patients who are receiving oral bisphosphonate therapy. The Journal of the American Dental Association published the resulting report in 2006. This 2008 advisory statement is the first of projected periodic updates of the 2006 clinical recommendations. CONCLUSION This 2008 advisory statement concludes, on the… 

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.

The benefit provided by antiresorptive therapy outweighs the low risk of developing osteonecrosis of the jaw, and an oral health program consisting of sound hygiene practices and regular dental care may be the optimal approach for lowering ARONJ risk.

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.

World Workshop on Oral Medicine VI: Controversies regarding dental management of medically complex patients: assessment of current recommendations.

American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

  • S. RuggieroT. Dodson F. O'ryan
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2014

The use of bisphosphonates in children: review of the literature and guidelines for dental management.

This paper aims to outline paediatric uses and adverse effects of bisphosphonates and present recommendations on the dental management of children receiving bisph phosphonates.

Postmenopausal females and the link between oral bisphosphonates and osteonecrosis of the jaw: A clinical review

Oral bisphosphonates are commonly prescribed by NPs for postmenopausal females with the diagnosis of osteoporosis to arrest bone loss and preserve bone density and have shown a link between these medications and osteonecrosis of the jaw, which is a complication resulting in necrotic bone inside the mouth.

A review of the clinical implications of bisphosphonates in dentistry.

The present paper briefly describes the postulated pathophysiology of ONJ and conditions with similar clinical presentations, and the implications of bisphosphonate use in the dental clinical setting are still being determined.

Guidelines for bisphosphonate-associated osteonecrosis of the jaw

A consensus-based guideline was developed by a multidisciplinary task force including representatives from national and international societies representing the disciplines of oral surgery, dentistry, oral pathology, oral medicine, endocrinology, rheumatology and oncology for the diagnosis of bisphosphonate-associated osteonecrosis of the jaw.

Bisphosphonate‐Associated Osteonecrosis of the Jaw: Patient Care Considerations Overview for the Orthopaedic Nursing Healthcare Professional

The pathophysiology of ONJ is overview, the proposed causal relationship between BSP use and ONJ, and the current guidelines for dental care of a patient who will be, or is taking, this class of medications are outlined.

How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.

People taking bisphosphonates may be unfamiliar with the drug and its possible adverse oral side effects, and dentists should be prepared to educate patients about the risks of developing oral complications resulting from bisph phosphonate use and the need for appropriate dental care.
...

References

SHOWING 1-10 OF 16 REFERENCES

Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report.

This case suggests that patients under long-term oral bisphosphonate use should be treated with caution and well-controlled, prospective clinical trials on the effect of oral bisPhosphonates on bone are warranted to determine which patients may be at risk for such complications.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.

Doctors and dentists must be aware of the higher frequency of adverse jaw effects in patients receiving IV BPs, especially osteonecrosis of the jaw, and more clinical studies are needed to replicate and clarify the observed associations over long follow-up periods.

Orthodontic treatment of patients using bisphosphonates: a report of 2 cases.

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

The occurrence of ONJ is rare in a PMO population, and delayed healing of lesions can occur with and without bisphosphonate use over three years, and there is no evidence to suggest that healthy patients with osteoporosis who are receiving bisph phosphonates require any special treatment beyond routine dental care or to support altering standard treatment practices.

Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.

In this cohort of elderly cardiovascular patients, an association was observed between oral bisphosphonate use and aseptic osteonecrosis and further research into this putative association is required.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures and was associated with a significant improvement in bone mineral density and bone metabolism markers.

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

Dr. John Bilezikian asks whether there is a relationship between bisphosphonates and osteonecrosis of the jaw and what might explain it.

Epidemiology and outcomes of osteoporotic fractures